SEHK:1672Biotechs
Ascletis Pharma (SEHK:1672) Flags A Wider H1 2026 Loss, Is It Fully Priced?
Ascletis Pharma (SEHK:1672) told investors it expects a larger loss for the six months to June 30, 2026, as higher research and development spending supports its metabolic disease pipeline.
The guidance arrived after a strong 30 day share price return of 14%, although the stock remains down 29% over 90 days and the 1 year total shareholder return is also lower. Over the longer term, the 3 year and 5 year total shareholder returns are still very strong. This suggests that recent weakness may...